Full metadata record
| DC Field | Value | Language | 
|---|---|---|
| dc.contributor.author | El-Din, Mahmoud M. Gamal | - | 
| dc.contributor.author | El-Gamal, Mohammed I. | - | 
| dc.contributor.author | Abdel-Maksoud, Mohammed S. | - | 
| dc.contributor.author | Yoo, Kyung Ho | - | 
| dc.contributor.author | Oh, Chang-Hyun | - | 
| dc.date.accessioned | 2024-01-20T08:01:04Z | - | 
| dc.date.available | 2024-01-20T08:01:04Z | - | 
| dc.date.created | 2022-01-10 | - | 
| dc.date.issued | 2015-01-27 | - | 
| dc.identifier.issn | 0223-5234 | - | 
| dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/125848 | - | 
| dc.description.abstract | Synthesis of a new series of 1,3,4-oxadiazole derivatives possessing sulfonamide moiety is described. Their in vitro antiproliferative activities against NCI-58 human cancer cell lines of nine different cancer types were tested. Compound 1k with p-methoxybenzenesulfonamido moiety showed the highest mean %inhibition value over the 58 cell line panel at 10 mu M concentration. It showed broad-spectrum antiproliferative activity over many cell lines of different cancer types. For instance, compound 1k inhibited the growth of T-47D breast cancer cell line by 90.47% at 10 mu M. And it inhibited growth of SR leukemia, SK-MEL-5 melanoma, and MDA-MB-468 breast cancer cell lines by more than 80% at the same test concentration. Compound 1k showed superior activity than Paditaxel and Gefitinib against the most sensitive cell lines. (C) 2014 Elsevier Masson SAS. All rights reserved. | - | 
| dc.language | English | - | 
| dc.publisher | ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER | - | 
| dc.subject | BIOLOGICAL EVALUATION | - | 
| dc.subject | ANTICANCER ACTIVITY | - | 
| dc.subject | BEARING OXADIAZOLE | - | 
| dc.subject | DESIGN | - | 
| dc.subject | AGENTS | - | 
| dc.subject | INHIBITORS | - | 
| dc.subject | CANCER | - | 
| dc.subject | NUCLEUS | - | 
| dc.subject | SERIES | - | 
| dc.subject | ACID | - | 
| dc.title | Synthesis and in vitro antiproliferative activity of new 1,3,4-oxadiazole derivatives possessing sulfonamide moiety | - | 
| dc.type | Article | - | 
| dc.identifier.doi | 10.1016/j.ejmech.2014.11.011 | - | 
| dc.description.journalClass | 1 | - | 
| dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, v.90, pp.45 - 52 | - | 
| dc.citation.title | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | - | 
| dc.citation.volume | 90 | - | 
| dc.citation.startPage | 45 | - | 
| dc.citation.endPage | 52 | - | 
| dc.description.journalRegisteredClass | scie | - | 
| dc.description.journalRegisteredClass | scopus | - | 
| dc.identifier.wosid | 000348951900005 | - | 
| dc.identifier.scopusid | 2-s2.0-84910110586 | - | 
| dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - | 
| dc.relation.journalResearchArea | Pharmacology & Pharmacy | - | 
| dc.type.docType | Article | - | 
| dc.subject.keywordPlus | BIOLOGICAL EVALUATION | - | 
| dc.subject.keywordPlus | ANTICANCER ACTIVITY | - | 
| dc.subject.keywordPlus | BEARING OXADIAZOLE | - | 
| dc.subject.keywordPlus | DESIGN | - | 
| dc.subject.keywordPlus | AGENTS | - | 
| dc.subject.keywordPlus | INHIBITORS | - | 
| dc.subject.keywordPlus | CANCER | - | 
| dc.subject.keywordPlus | NUCLEUS | - | 
| dc.subject.keywordPlus | SERIES | - | 
| dc.subject.keywordPlus | ACID | - | 
| dc.subject.keywordAuthor | Antiproliferative activity | - | 
| dc.subject.keywordAuthor | 1,3,4-Oxadiazole | - | 
| dc.subject.keywordAuthor | Sulfonamide | - | 
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.